Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Talent Hub
    • Talent Hub
    • Alberta Petri Dish
    • WIL
    • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Alberta at Bio International 2022
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Print This Page


Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos' lead candidate. Entos will use the NanoAssemblr Blaze™ instrument for preclinical toxicology studies and transition to the NanoAssemblr Scale-Up system for GMP manufacturing of the drug product for clinical studies. PNI will work closely with the Entos team to provide a complete solution with instrumentation tailored to their needs, expertise and services for formulation scale-up and transition to clinical manufacturing towards phase I study. Financial terms of the agreement were not disclosed.


Read full press release details.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link